Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/CwlSvBXaXiE   A third dose of the Pfizer CoVid vaccine reduces the risk of a severe CoVid infection by 92%, a hospitalization for CoVid by 93%, and a CoVid-related death by 81%.  These conclusions come from a massive study by Israel’s Clalit Institute in collaboration with the Harvard Medical School.   The researchers studied nearly 1.5 million persons from the end of July through late September, 2021 when Delta was the predominant version of CoVid in Israel.  Half the group received the 3rd dose of Pfizer as a booster and the other half of matched controls only received the 2 dose initial vaccination.   The benefits of receiving a 3rd booster dose of the Pfizer vaccine began to appear as early as 7 days after vaccine and peaked at 49 days after the jab.  This was true  for protection against a breakthrough infection, hospitalization, and death.   The movement to offer CoVid vaccine boosters began in Europe as vaccine-induced CoVid immunity began waning 6 months following vaccinat